Nomura Holdings Inc Hutchmed (China) LTD Transaction History

Nomura Holdings Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $344,250 - $697,950	45,000 New	45,000 $665,000
Q1 2022 May 18, 2022	SELL	$15.52 - $35.65 $179,612 - $412,577	-11,573 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$28.89 - $35.33 $23,112 - $28,264	800 Added 7.43%	11,573 $406,000
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $56,093 - $67,544	1,573 Added 17.1%	10,773 $390,000
Q2 2021 Aug 16, 2021	SELL	$23.7 - $39.27 $7,110 - $11,781	-300 Reduced 3.16%	9,200 $306,000
Q1 2021 May 17, 2021	SELL	$27.01 - $36.8 $45,917 - $62,559	-1,700 Reduced 15.18%	9,500 $267,000
Q4 2020 Feb 16, 2021	SELL	$27.51 - $34.36 $1.23 Million - $1.54 Million	-44,800 Reduced 80.0%	11,200 $353,000
Q1 2020 May 15, 2020	BUY	$15.19 - $29.51 $850,640 - $1.65 Million	56,000 New	56,000 $1 Million
Q1 2020 May 14, 2020	SELL	$15.19 - $29.51 $170,128 - $330,512	-11,200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.17 - $25.95 $192,304 - $290,640	11,200 New	11,200 $283,000
Q2 2019 Aug 14, 2019	SELL	$22.0 - $31.78 $250,800 - $362,292	-11,400 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$21.27 - $30.58 $242,478 - $348,612	11,400 New	11,400 $349,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.